• Bommier, E., Chapat, L., Guiot, A.L., Hilaire, F., Cariou, C., Poulet, H., Pialot, D., De Luca, K., 2020. Multivariate analysis of the immune response to different rabies vaccines. Vet. Immunol. Immunopathol. 220, 109986.

  • China CDC, 2016. Technical guidelines for human rabies prevention and contro. https://www.chinacdc.cn/zxdt/201602/t20160201_125012.html (accessed on 20 June 2021).

  • Douglas S, Lyles IVK, Rupprecht CE. 2013. Rhabdoviridae, p 885-922. In Knipe DM, Howley PM, Cohen JL, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields Virology, 6th ed, vol 1. Lippincott Williams and Wilkens, Philadelphia, PA

  • Ertl, H.C.J., 2019. New rabies vaccines for use in humans. Vaccines (Basel) 7 (2), 54.

  • Ge, J., Wang, X., Tao, L., Wen, Z., Feng, N., Yang, S., Xia, X., Yang, C., Chen, H., Bu, Z., 2011. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85, 8241-8252.

  • Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., Cleaveland, S., Costa, P., Freuling, C.M., Hiby, E., Knopf, L., Leanes, F., Meslin, F.X., Metlin, A., Miranda, M.E., Muller, T., Nel, L.H., Recuenco, S., Rupprecht, C.E., Schumacher, C., Taylor, L., Vigilato, M.A., Zinsstag, J., Dushoff, J., Global Alliance for Rabies Control Partners for Rabies, P, 2015. Estimating the global burden of endemic canine rabies. PLoS Neglected Trop. Dis. 9, e0003709.

  • Lawson, N.D., Stillman, E.A., Whitt, M.A., Rose, J.K., 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92, 4477-4481.

  • Lebrun, A., Garcia, S., Li, J., Kean, R.B., Hooper, D.C., 2017. Protection against CNStargeted rabies virus infection is dependent upon type-1 immune mechanisms induced by live-attenuated rabies vaccines. Tropical Med. Infect. Dis. 2, 22.

  • Li, Y., Zhao, L., Sui, B., Luo, Z., Zhang, Y., Wang, Y., 2020. Recombinant rabies virus overexpressing OX40-ligand enhances humoral immune responses by increasing T follicular helper cells and germinal center B cells. Vaccines 8, 144.

  • Park, J.E., Shin, H.J., 2021. Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice. Vet. Q. 41, 202-209.

  • Singh, R., Singh, K.P., Cherian, S., Saminathan, M., Kapoor, S., Manjunatha Reddy, G.B., Panda, S., Dhama, K., 2017. Rabies-epidemiology, pathogenesis, public health concerns and advances in diagnosis and control:a comprehensive review. Vet. Q. 37, 212-251.

  • WHO, 2013. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser, pp. 1-139. back cover.

  • Wu, C., Wu, M., Liang, M., Xiong, S., Dong, C., 2019. A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model. Cell. Mol. Immunol. 16, 780-782.

  • Wu, F., Fan, X., Yue, Y., Xiong, S., Dong, C., 2014. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine 32, 3917-3926.

  • Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E.B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., Avraham, R., Puni, R., Lupu, E., Bar-David, E., Sittner, A., Erez, N., Zichel, R., Mamroud, E., Mazor, O., Levy, H., Laskar, O., Yitzhaki, S., Shapira, S.C., Zvi, A., Beth-Din, A., Paran, N., Israely, T., 2020. A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 6402.

  • Zhang, Y., Yang, J., Li, M., Cui, M., Fu, Z.F., Zhao, L., Zhou, M., 2019. A recombinant rabies virus expressing fms-like tyrosine kinase 3 ligand (Flt3L) induces enhanced immunogenicity in mice. Virol. Sin. 34, 662-672.